Start with patients
Patient-derived samples, multiomic profiling, and AI-guided systems immunology reveal clinically grounded resistance mechanisms.
MIORG is a Finnish preclinical immuno-oncology company developing therapeutic programs for cancers that resist current immunotherapies.
We start with patient-derived tumor biology to identify why cancer immunotherapies succeed or fail. We then translate those insights into focused, biomarker-informed therapeutic programs for pharmaceutical partnering.
Our approach combines clinical relevance, functional immunology, and computational design to create programs with a clear biological rationale.
Patient-derived samples, multiomic profiling, and AI-guided systems immunology reveal clinically grounded resistance mechanisms.
Functional assays and preclinical models determine which mechanisms can become meaningful therapeutic opportunities.
Computational immunochemistry and therapeutic design turn validated biology into focused preclinical programs.
Cancer immunotherapy has transformed oncology, but many tumors remain resistant. MIORG is built to address this gap with patient-grounded discovery and partnership-ready preclinical development.
Programs begin with patient-derived biology, keeping the discovery process tied to real disease mechanisms.
Functional validation, biomarker rationale, and therapeutic design create a clearer path from insight to asset.
MIORG develops focused preclinical programs intended for licensing, co-development, and pharmaceutical partnerships.
MIO-36 is a monoclonal antibody program designed to engage innate immune activity in resistant tumor settings and help drive adaptive antitumor T-cell responses, creating a stronger biological foundation for rational immunotherapy combinations.
MIORG is building antibody and peptide programs around validated immune-resistance biology, biomarker-guided patient selection, and rational treatment combinations.
MIORG is led by Carlos Rogério Figueiredo, PhD, a cancer immunologist and translational scientist focused on discovering and targeting immune resistance mechanisms that limit the effectiveness of cancer immunotherapy.
The company is being built around reverse translational precision oncology, connecting patient-derived biology to therapeutic antibody and peptide assets intended for preclinical proof-of-concept and pharmaceutical partnering.